Cathie Wood's Ark Invest recommends Meta Platforms and Recursion Pharmaceuticals for AI investment

From Nasdaq: 2024-06-03 06:15:00

Wall Street is abuzz with excitement over the booming AI market. Cathie Wood’s Ark Invest has Meta Platforms (NASDAQ: META) and Recursion Pharmaceuticals (NASDAQ: RXRX) as top picks in the field. But should investors follow suit with these AI selections? Let’s delve into the details.

Meta Platforms is making waves in the AI space, with initiatives like the AI-powered Reels contributing to its financial success. The company’s large language model, Llama, and virtual assistant, Meta AI, show promising potential. Despite being a major player in AI, Meta Platforms’ revenue primarily stems from advertising, with a user base of 3.24 billion daily active users as of Q1.

Recursion Pharmaceuticals is leveraging AI to hasten the drug development process, aiming to bring innovative medicines to market quicker. Collaborations with Bayer and Nvidia highlight its focus on revolutionizing healthcare through AI. While still in the early stages, Recursion Pharmaceuticals remains a high-risk investment, especially in the clinical-stage biotech sector.

Investors eyeing Meta Platforms should consider the Motley Fool Stock Advisor’s top 10 stock picks, which do not include the company. This service has historically outperformed the S&P 500, offering expert guidance and regular stock updates. With past picks like Nvidia yielding significant returns, the Stock Advisor service presents a promising investment opportunity for those seeking growth.

Randi Zuckerberg, former Facebook executive and sister of Meta Platforms CEO Mark Zuckerberg, sits on The Motley Fool’s board. Prosper Junior Bakiny, a Meta Platforms investor, highlights the company’s potential. The Motley Fool, endorsing Meta Platforms and Nvidia, offers transparent disclosure policies for investors seeking reliable information.



Read more at Nasdaq: Cathie Wood Owns These 2 AI Stocks. Should You?